Sygnature Discovery and Pneumolabs Establish A Strategic Alliance
Advertisement
Sygnature Discovery Limited and Pneumolabs (UK) Limited announced they have entered into a strategic alliance. Under the terms of the agreement, Sygnature and Pneumolabs will collaborate to provide a fully-integrated drug discovery service to accelerate clients’ drug discovery programmes into development. This new alliance complements Sygnature’s existing strategic alliances with Cyprotex Discovery, a centre of excellence for in vitro ADME/toxicology, and Saretius, a pre-clinical experimental services company offering ‘gold standard’ techniques in pain, metabolic and CNS disorders, inflammatory disease and in vivo pharmacokinetics.